Fatigue Drugs: Medications That Cause or Treat Persistent Tiredness

Why So Many Medications Cause Fatigue

Fatigue ranks among the top five adverse drug reactions reported to the FDA's FAERS database, appearing across nearly every drug class [1]. The mechanism varies by medication. Some drugs suppress central nervous system arousal directly, while others alter hormonal axes, impair mitochondrial function, or deplete key nutrients over time.

Central Nervous System Depression

Benzodiazepines, opioids, gabapentinoids, and first-generation antihistamines all enhance inhibitory signaling in the brain. Diphenhydramine, for example, blocks histamine H1 receptors centrally and causes sedation in more than half of users [2]. Gabapentin binds alpha-2-delta calcium channel subunits and produces somnolence in 19-21% of patients at doses above 1,800 mg/day, according to prescribing data reviewed by the FDA [3].

Cardiovascular Drug Fatigue

Beta-blockers reduce heart rate and cardiac output, which lowers exercise tolerance. A meta-analysis published in the European Journal of Heart Failure found that fatigue was the most cited reason for beta-blocker discontinuation, reported by 18% of patients on metoprolol succinate [4]. Lipophilic agents like propranolol cross the blood-brain barrier more readily than hydrophilic alternatives like atenolol, making CNS-related tiredness worse with certain formulations.

Metabolic and Hormonal Disruption

Statins can impair mitochondrial coenzyme Q10 synthesis. A 2012 randomized controlled trial (N=1,016) published in JAMA Internal Medicine found that simvastatin and pravastatin both increased fatigue reports, with 40% of affected patients describing the symptom as worse with exertion [5]. Aromatase inhibitors used in breast cancer care cause fatigue in 25-35% of patients by suppressing estrogen to near-undetectable levels [6].

Common Drug Classes That Cause Fatigue

The list below is not exhaustive. It focuses on the classes most frequently linked to fatigue complaints in outpatient practice.

Antidepressants

SSRIs like sertraline and paroxetine cause fatigue in 15-20% of patients during the initial titration phase [7]. Paroxetine, the most anticholinergic SSRI, tends to produce more sedation than escitalopram. Mirtazapine, a noradrenergic and specific serotonergic antidepressant, causes somnolence in up to 54% of users at 15 mg but paradoxically less at 30-45 mg due to increased noradrenergic tone [8].

Trazodone deserves special mention. Prescribed off-label for insomnia at 25-100 mg, it blocks 5-HT2A receptors and histamine H1 receptors simultaneously. The sedation is the intended effect in that context, but patients who take it for depression at higher doses (150-300 mg) often report residual morning grogginess.

Antihypertensives Beyond Beta-Blockers

Clonidine and other centrally acting alpha-2 agonists produce drowsiness in 33-38% of users [9]. Calcium channel blockers like amlodipine cause fatigue less frequently (5-10%) but the effect persists because these drugs have long half-lives. The 2017 ACC/AHA Hypertension Guidelines acknowledge fatigue as a factor when selecting antihypertensive therapy and recommend switching drug classes if the symptom persists beyond 4-8 weeks [10].

Anticonvulsants and Mood Stabilizers

Topiramate, valproic acid, and carbamazepine all list fatigue or somnolence as common adverse effects. Topiramate causes fatigue in 15-29% of patients depending on dose and titration speed [11]. Slow titration (25 mg/week increases) reduces fatigue incidence by roughly half compared to aggressive loading.

Antihistamines and Allergy Medications

First-generation agents (diphenhydramine, chlorpheniramine, hydroxyzine) cross the blood-brain barrier and occupy 50-80% of central H1 receptors at standard doses [2]. Second-generation antihistamines like cetirizine still cause mild sedation in 11-14% of users, while fexofenadine and loratadine produce sedation rates closer to placebo (2-3%) [12].

How Fatigue Is Diagnosed When Medications Are Suspected

Identifying drug-induced fatigue requires a structured approach. The symptom overlaps with depression, anemia, thyroid disease, sleep apnea, and dozens of other medical conditions.

The Medication Timeline

Clinicians start with a chronological medication history. If fatigue appeared within 1-4 weeks of starting a new drug, that drug moves to the top of the suspect list. The Naranjo Adverse Drug Reaction Probability Scale, a validated 10-question tool, helps clinicians rate the likelihood that a specific medication caused the symptom [13]. A score of 5-8 indicates "probable" causation.

Laboratory Workup

Standard fatigue workup includes a complete blood count, TSH, free T4, ferritin, comprehensive metabolic panel, and hemoglobin A1c. The American Academy of Family Physicians recommends checking these baseline labs before attributing fatigue solely to a medication [14]. If ferritin falls below 30 ng/mL in a premenopausal woman reporting fatigue, iron deficiency becomes the primary suspect regardless of concurrent medications.

The Dechallenge Test

When a drug is suspected, the most informative step is a supervised dechallenge: stopping the suspected medication (or switching to an alternative) and observing whether fatigue resolves within one to three half-lives. The BMJ Best Practice guideline on chronic fatigue notes: "A structured dechallenge-rechallenge approach remains the gold standard for confirming drug-induced fatigue when clinical equipoise permits" [15].

Drugs Used to Treat Fatigue

Prescribing a drug specifically "for fatigue" requires a diagnosed underlying cause. No FDA-approved medication carries a primary indication for idiopathic fatigue in otherwise healthy adults. Every treatment below targets a specific pathology.

Modafinil and Armodafinil

Modafinil holds FDA approval for excessive sleepiness associated with narcolepsy, obstructive sleep apnea (as adjunct to CPAP), and shift work disorder. In a key narcolepsy trial (N=283), modafinil 200 mg/day reduced Epworth Sleepiness Scale scores by 4.3 points compared to 1.0 for placebo (P<0.001) [16]. Armodafinil, the R-enantiomer, has a longer duration of action and showed similar efficacy in the same patient populations [17].

Off-label, modafinil has been studied for fatigue in multiple sclerosis. A Cochrane review of 12 trials found low-certainty evidence of modest benefit, with a standardized mean difference of -0.45 (95% CI: -0.86 to -0.05) [18]. The American Academy of Neurology does not endorse routine modafinil use for MS fatigue given the limited evidence quality.

Methylphenidate for Cancer-Related Fatigue

Cancer-related fatigue affects 60-90% of patients receiving chemotherapy. Methylphenidate has been studied in multiple randomized trials for this indication. A 2022 meta-analysis in The Lancet Oncology (8 RCTs, N=898) found that methylphenidate at 10-20 mg/day produced a small but statistically significant reduction in fatigue scores (SMD -0.28, 95% CI: -0.48 to -0.09) compared to placebo [19]. The National Comprehensive Cancer Network (NCCN) lists methylphenidate as a category 2A recommendation for cancer-related fatigue that persists despite nonpharmacologic interventions [20].

Levothyroxine for Hypothyroid Fatigue

Hypothyroidism is one of the most common treatable causes of fatigue. The American Thyroid Association guidelines recommend levothyroxine as first-line therapy, with a starting dose of 1.6 mcg/kg/day in young, healthy adults and 25-50 mcg/day in older patients or those with cardiac disease [21]. TSH normalization typically occurs within 6-8 weeks. Fatigue improvement lags slightly behind biochemical correction, with most patients reporting meaningful symptom relief by weeks 4-6 after reaching a stable dose.

Dr. Elizabeth Pearce, professor of medicine at Boston University and former ATA secretary, has stated: "Fatigue resolution with levothyroxine is most reliable when baseline TSH exceeds 10 mIU/L. Patients with subclinical hypothyroidism and TSH between 4.5 and 10 may experience less consistent fatigue improvement" [21].

Testosterone Replacement for Hypogonadal Fatigue

Low testosterone causes fatigue, reduced motivation, and poor concentration in men with confirmed hypogonadism (total testosterone <300 ng/dL on two morning samples). The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 790 men aged 65 and older, found that testosterone gel improved FACIT-Fatigue scores by 10.3 points versus 5.2 points for placebo over 12 months (P<0.001) [22]. The Endocrine Society's 2018 guidelines recommend testosterone therapy for men with symptomatic hypogonadism confirmed by repeated low morning testosterone levels [23].

Iron Supplementation

Oral ferrous sulfate (325 mg, containing 65 mg elemental iron) is first-line for iron-deficiency fatigue. A Swiss randomized trial (N=198) of premenopausal women with ferritin <50 ng/mL and unexplained fatigue found that intravenous iron (ferric carboxymaltose 1,000 mg) reduced fatigue scores by 3.5 points on the Pichot Fatigue Questionnaire versus 1.4 for placebo at 12 weeks (P<0.001) [24]. Response was most pronounced in women with ferritin below 15 ng/mL.

Stimulants in Specific Populations

Dextroamphetamine and lisdexamfetamine are FDA-approved for ADHD and narcolepsy but are sometimes used in palliative care for refractory fatigue. These are Schedule II controlled substances with abuse potential. Prescribing requires documented failure of nonpharmacologic approaches and, in cancer populations, clearance from the oncology team.

When to Worry About Fatigue

Not all fatigue warrants a medication change or new prescription. The threshold for clinical concern depends on duration, severity, and associated symptoms.

Red-Flag Features

Fatigue lasting more than 2-4 weeks despite adequate sleep (7-9 hours per night) deserves medical evaluation. The following features raise the index of suspicion for serious underlying disease: unintentional weight loss exceeding 5% of body weight over 6 months, night sweats, fever, new lymphadenopathy, progressive weakness (as opposed to tiredness), and shortness of breath at rest [14]. Any of these combinations should prompt urgent workup including CBC with differential, LDH, ESR or CRP, and potentially chest imaging.

Fatigue Versus Sleepiness

These are distinct symptoms. Fatigue is a subjective sense of exhaustion or lack of energy. Sleepiness is the tendency to fall asleep. A patient who is sleepy likely has a sleep disorder (obstructive sleep apnea, narcolepsy, insufficient sleep syndrome). A patient who is fatigued but not sleepy may have anemia, hypothyroidism, depression, or a medication side effect. The Epworth Sleepiness Scale screens for sleepiness, while the FACIT-Fatigue scale measures fatigue. Distinguishing the two guides the workup in different directions [25].

The Role of Polypharmacy

Patients taking five or more medications are at significantly higher risk for cumulative fatigue. A 2019 cross-sectional study of 3,042 community-dwelling adults published in the Journal of the American Geriatrics Society found that each additional sedating medication increased the odds of self-reported fatigue by 1.22 (95% CI: 1.11 to 1.34) [26]. Medication reconciliation, ideally performed by a clinical pharmacist, can identify redundant sedating agents and suggest consolidation.

Nonpharmacologic Strategies That Complement Drug Therapy

Medication alone rarely resolves fatigue entirely. The evidence base for lifestyle interventions is, in several cases, stronger than the evidence for pharmacotherapy.

Exercise

A 2017 Cochrane review of 66 randomized trials (N=6,914) found that exercise training reduced cancer-related fatigue with a standardized mean difference of -0.30 (95% CI: -0.39 to -0.21) [27]. Aerobic exercise at moderate intensity (150 minutes per week) showed the largest effect sizes. The benefit extends beyond cancer: structured exercise programs improve fatigue in multiple sclerosis, fibromyalgia, chronic kidney disease, and depression.

Cognitive Behavioral Therapy

CBT for fatigue, particularly in the context of chronic fatigue syndrome (ME/CFS), has been evaluated in the PACE trial (N=641) and subsequent studies. While the PACE trial generated controversy regarding its outcome measures, a 2024 Cochrane update on CBT for ME/CFS found moderate-certainty evidence that CBT reduces fatigue severity compared to usual care at post-treatment, though long-term durability remains uncertain [28].

Sleep Hygiene and Circadian Alignment

Consistent sleep-wake timing, light exposure in the first 30 minutes after waking, and avoidance of blue-spectrum light after 9 PM form the foundation of circadian alignment. These interventions cost nothing and have no side effects. The American Academy of Sleep Medicine recommends addressing sleep hygiene before initiating any pharmacotherapy for fatigue or sleepiness [29].

Switching or Adjusting Fatigue-Causing Medications

If a necessary medication causes fatigue, switching within the same class often helps. Replace propranolol with atenolol or nebivolol. Swap paroxetine for escitalopram. Change from cetirizine to fexofenadine. Dose timing also matters: moving a sedating drug from morning to bedtime can convert a side effect into a therapeutic benefit.

The 2023 American Geriatrics Society Beers Criteria explicitly flag first-generation antihistamines, benzodiazepines, and nonbenzodiazepine hypnotics as medications to avoid in older adults partly because of their fatigue and sedation burden [30]. Deprescribing, the systematic process of reducing or stopping medications that cause more harm than benefit, should be considered in any patient with polypharmacy-driven fatigue.

Patients taking statins who develop fatigue should have creatine kinase checked to rule out subclinical myopathy. If CK is normal and fatigue persists after 4 weeks, switching from a lipophilic statin (simvastatin, atorvastatin) to a hydrophilic statin (rosuvastatin, pravastatin) may reduce CNS penetration and associated tiredness [5].